drugset
drugset / Trial / NCT07852130

Reliability of Standardized IQ Testing Under Modafinil, Racetam-Class Compounds, Sleep Restriction and Daily Activity

NCT07852130 ↗

Phase 1 Completed 70 enrolled Abdulraheem Mohamed Gouda
RandomizedParallel-groupDouble-blindBasic science

Summary

This study examined whether standardized IQ test scores in healthy adults aged 18-35 are stable measures of cognitive ability and evaluated whether standardized cognitive-test performance and response-initiation measures vary across pharmacological and sleep conditions. Seventy healthy volunteers were assessed at seven in-person timepoints over six months, with 25 participants receiving an inert matched preparation and 45 receiving modafinil or one of four racetam-class compounds (oxiracetam, pramiracetam, phenylpiracetam, aniracetam) administered orally before testing. A different standardized instrument was administered at each timepoint to limit item-level recall and practice effects, and change in the placebo group was used as the reference for estimating practice effects. Participants were assessed under both rested and sleep-restricted conditions, two psychologists were present at every administration to code response initiation (hesitation), and physiological state was monitored using a consumer wearable. Psychometric changes were evaluated relative to the standard error of measurement of the instruments and the study's prespecified minimum detectable effect. Response-initiation measures were analysed separately from psychometric scores to evaluate potential effects on response initiation and execution time.

Timeline

Start
2026-03-09
Primary completion
2026-09-09
Completion
2026-09-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Modafinil Small molecule — Oral
Subject Oxiracetam Small molecule 100 mg Oral
Subject Oxiracetam Small molecule 200 mg Oral
Subject Oxiracetam Small molecule 300 mg Oral
Subject aniracetam Small molecule 100 mg Oral
Subject aniracetam Small molecule 200 mg Oral
Subject aniracetam Small molecule 300 mg Oral
Subject phenylpiracetam Unknown 100 mg Oral
Subject phenylpiracetam Unknown 200 mg Oral
Subject phenylpiracetam Unknown 300 mg Oral
Subject pramiracetam Small molecule 100 mg Oral
Subject pramiracetam Small molecule 200 mg Oral
Subject pramiracetam Small molecule 300 mg Oral

Indications

No indication recorded.